Cancer Family
Malignant Bone Marrow Neoplasm
CI-CAN-00000226Explore in graph →
1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000226Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (801)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04202003 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 105 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02340884 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | completed | Phase 2 | 92 | Seattle Children's HospitalOTHER | 1 | Apr 9, 2024 |
| clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT04767802 | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit(PACIFIC) | completed | Phase 2 | 20 | Protagonist Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00235560 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients(LAM-RAPA) | completed | Phase 2 | 50 | University Hospital, ToulouseOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02789254 | FLYSYN in MRD Positive AML(FLYSYN-101) | completed | Phase 1 / Phase 2 | 31 | Synimmune GmbHINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT02626338 | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | completed | Phase 1 / Phase 2 | 16 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT02400255 | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | completed | Phase 2 | 30 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03734601 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT02509546 | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03455517 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia(VeRitAs) | completed | Phase 2 | 77 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03961919 | Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant(FLAT-Auto) | completed | Phase 2 | 15 | Ciceri FabioOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03613727 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | completed | Phase 2 | 61 | Virginia Commonwealth UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04055844 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | completed | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02989844 | Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | completed | Phase 2 | 20 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT01404741 | 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 191 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02117297 | SCT Plus Immune Therapy in Average Risk AML/MDS | completed | Phase 2 | 26 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02221310 | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | completed | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT00611351 | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | completed | Phase 2 | 5 | University of NebraskaOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03701295 | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | completed | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01712308 | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT01056523 | Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 29 | Jewish General HospitalOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT02073838 | Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | completed | Phase 2 | 23 | Sarit AssoulineOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT02771197 | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | completed | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03625388 | Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | completed | Phase 2 | 56 | Hikma Pharmaceuticals LLCINDUSTRY | 4 | Sep 22, 2023 | clinicaltrials |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | completed | Phase 2 | 202 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00106600 | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 12 | CTI BioPharmaINDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT01696461 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | completed | Phase 2 | 127 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT02873338 | Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 75 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03390296 | OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT03531918 | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm | completed | Phase 1 / Phase 2 | 66 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04712942 | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | completed | Phase 2 | 14 | University of LeipzigOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03030612 | A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 38 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT00516828 | Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 21 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT01772420 | Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia | completed | Phase 2 | 52 | Albert Einstein College of MedicineOTHER | 1 | Jul 27, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2024source: clinicaltrials